Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal MPI Acquisition Time with Apadenoson
NCT00162071Phase 2Terminated
- Sponsor
- Forest Laboratories
- Start
- Jul 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apadenoson in ischemic heart disease (IHD), sponsored by Forest Laboratories. Started Jul 2005; status: terminated.
02
Drugs
apadenoson
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT00162071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162071.